Dr Reddy’s Laboratories Ltd has entered into a strategic collaboration with global biotechnology company Amgen to market and distribute three Amgen medicines in India in the areas of oncology and cardiology.
Under the terms of the collaboration, Dr Reddy’s shall perform a full range of regulatory and commercial services to seek approval and launch Kyprolis (carfilzomib), BLINCYTO (blinatumomab) and Repatha (evolocumab) in the domestic market.
The collaboration leverages the capabilities of both companies, combining three of Amgen’s innovative therapies with Dr Reddy’s deep understanding of patient and physician needs in India.
“Addressing significant unmet needs of patients in oncology and cardiovascular are key areas in India and, therefore, a priority for us at Dr Reddy’s,’’ Alok Sonig, Dr Reddy’s Executive Vice President and Head of India Business said in a release on Thursday.
“We are pleased to be joining forces with Dr. Reddy’s Laboratories in order to make Amgen’s innovative medicines available to patients in India,” said Penny Wan, Amgen vice president and general manager, Japan Asia Pacific Region.